<DOC>
	<DOCNO>NCT00494988</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial evaluate remission rate newly diagnose subject type 2 diabetes short-term intensive treatment insulin aspart insulin NPH .</brief_summary>
	<brief_title>Self-control Trial Evaluate Remission Rate Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes newly diagnose within 612 month FBG : 11.117.0 mmol/L Body mass index ( BMI ) large 25.0 kg/m2 Known suspect allergy trial product ( ) relate product Recurrent major hypoglycaemia judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>